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The diameter of thoracic aortic aneurysm (AA) is at least 
1.5 times that of a normal thoracic aorta (1). Sixty percent of 
thoracic AAs occur in the aortic root and/or the ascending 
aorta, 40% occur in the descending aorta, 10% occur in 
the aortic arch, and 10% occur in the thoracoabdominal 
aorta (2). Patients with thoracic AA are at increased risk for 
aortic dissection if they have high blood pressure, especially 
not controlled, dyslipidemia, smoking, use of cocaine and 
other stimulants which increase aortic wall stress, weight 
lifting, trauma, aortic coarctation, pheochromocytoma, 
and disorders with abnormalities of the aortic media (3). 
Other causes for thoracic aortic dissection are pregnancy, 
polycystic renal disease, chronic use of corticosteroids or 
immunosuppressant drugs, and aortic wall infections (3).
Persons with thoracic AA must be counseled about 
smoking cessation and referred to a smoking cessation 
program with either use of nicotine replacement, varenicline, 
or bupropion (3). These patients must also avoid exposure to 
passive smoking. Current cigarette smoking is a major risk 
factor for development of thoracic AA.
Dyslipidemia must be treated. Atorvastatin 40 to 
80 mg daily or rosuvastatin 20 to 40 mg daily should 
be administered to persons with thoracic AA (4). Of 
649 persons, mean age 70.3 years, with a thoracic AA, 
147 (23%) were treated with statins (5). At a median follow-
up of 3.6 years, statins reduced all-cause mortality by 32% 
from 33% to 20% and the composite end-point of all-
cause mortality, rupture, dissection, or repair 28% from 
75% to 59% (5). In another study of 1,560 patients, mean 
age 63 years, with thoracic AAs, 369 (24%) were treated 
with statins (6). The patients treated with statins had a 44% 
reduction in surgery within 10 years (6). In this study, use of 
angiotensin receptor blockers reduced surgery by 34%, and 
use of beta blockers reduced surgery by 31% (6) 
Hypertension must be controlled to decrease myocardial 
infarction, stroke, heart failure, death from cardiovascular 
causes, and aortic dissection (3,7-12). The blood pressure 
in persons with thoracic AA should be lowered to less 
than 130/80 mmHg. A beta blocker plus an angiotensin-
converting enzyme inhibitor or angiotensin receptor 
blocker should be administered to these persons (3,7). Beta 
blockers lower blood pressure and also reduce peak left 
ventricular ejection rate. By decreasing left ventricular dP/dt 
and decreasing shear stress, beta blockers decrease the rate 
of aortic dilatation (12). Beta blockers also decrease dP/dt 
and shear stress in the aorta (12). Persons with Marfan’s 
syndrome should also be treated with beta blockers (3,13) 
and with losartan (3,14) to lower aortic dilatation.
If  there are symptoms suggest ing thoracic  AA 
expansion, surgical intervention should be considered. If 
the ascending thoracic aorta or aortic sinus diameter is 
5.5 cm or more in an asymptomatic surgical candidate who 
has a degenerative thoracic AA, chronic aortic dissection, 
intramural hematoma, penetrating atherosclerotic ulcer, 
mycotic aneurysm, or pseudoaneurysm, surgery should 
be performed (3). Asymptomatic persons with genetic 
conditions such as Marfan's syndromes should have elective 
surgery if their diameters are 4.0 to 5.0 cm depending 
on the disorder to prevent acute dissection or rupture 
(3,15,16). Asymptomatic women who have Marfan’s 
syndrome desiring to become pregnant should have surgical 
intervention to replace their aortic root and ascending 
aorta if their ascending thoracic aorta diameter is greater 
than 4.0 cm (3). Asymptomatic persons with Marfan’s 
syndrome should be treated with surgical intervention if 
their ascending thoracic aortic diameter is 5.0 cm or more 
and with <5.0 cm if there is a family history of dissection 
or an increase in ascending thoracic aortic diameter greater 
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than 0.5 cm per year (3). Asymptomatic persons who have 
Loeys-Dietz syndrome should be treated with surgical 
intervention if their ascending thoracic aortic diameter is 
≥4.2 cm by transesophageal echocardiography or 4.4 to 
4.6 cm by cardiac computed tomography or cardiac 
magnetic resonance (3). If the increase in the ascending 
thoracic aortic diameter is greater than 0.5 cm per 
year in an asymptomatic person with a diameter below 
5.5 cm, surgical intervention should be performed (3). 
Asymptomatic persons with bicuspid aortic valve should 
have surgical intervention if the diameter of their aortic 
sinuses or ascending thoracic aorta is >5.5 or >5.0 cm with a 
family history of aortic dissection or an increase in diameter 
≥0.5 cm/year (17). The ascending thoracic aorta should be 
replaced in persons with bicuspid aortic valve having aortic 
valve surgery if their ascending thoracic aorta diameter is 
>4.5 cm (17).
If thoracic aorta dissection develops, decrease aortic 
shear stress and decide which persons should have surgical 
intervention or endovascular repair (3). Beta blockers are the 
initial drug of choice for lowering blood pressure, ventricular 
rate, dP/dt, and stress on the aorta (3,18,19). Systolic 
blood pressure should be lowered to 100 to 120 mmHg 
and the ventricular rate lowered to <60 beats/minute 
by intravenous propranolol, metoprolol, labetalol, or 
esmolol (3,19). Intravenous verapamil or diltiazem may be 
administered to persons intolerant to treatment with beta 
blockers (3,19). If more antihypertensive drugs are needed 
to lower the systolic blood pressure to 100 to 120 mm Hg, 
treat these patients with intravenous sodium nitroprusside, 
nicardipine, nitroglycerin, or fenoldopam (3,20).
Seventy-eight of 130 patients (60%) with aortic 
dissection type B were treated with medical treatment 
only (8). Seventy-one of these 78 patients (91%), mean 
age 64 years, were discharged from the hospital. During 
follow-up, hypertension was treated with beta blockers 
in 51patients and with other antihypertensive drugs in 
20 patients. During 4.2-year mean follow-up, 9 of 
51 patients (18%) treated with beta blockers and 11 of 
20 patients (55%) treated with other antihypertensive drugs 
needed dissection-related surgery (8).
A total of 1,301 patients with acute aortic dissection (722 
with type A dissection and 579 with type B dissection) were 
followed for ≤5 years (9). Treatment with beta blockers 
improved survival in patients with type A dissection and in 
patients with type B dissection (9). Treatment with calcium 
channel blockers improved survival in those with type B 
dissection (9).
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